A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors-Reference-Cited by-同舟云学术

A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors

Published:2019-02-04 Issue:3 Volume:145 Page:639-648
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Arnaud-Coffin Patrick¹²³,Maillet Denis¹²,Gan Hui K.⁴⁵⁶,Stelmes Jean-Jacques⁷,You Benoit¹²³,Dalle Stephane²³⁸,Péron Julien¹²³⁹¹⁰^ORCID

Affiliation:

1. Department of Medical Oncology; Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL); Pierre-Bénite France

2. Department of ImmuCare (Immunology Cancer Research); Institut de Cancérologie des Hospices Civils de Lyon; Lyon France

3. Faculté de Médecine Lyon-Sud; Lyon 1 University, EMR 3738; Oullins France

4. Olivia Newton-John Cancer Research Institute; Heidelberg VIC Australia

5. School of Cancer Medicine; La Trobe University; Heidelberg VIC Australia

6. Department of Medicine; Melbourne University; Melbourne VIC Australia

7. Department of Radiation Oncology; University Hospital of Zurich; Zürich Switzerland

8. Department of Dermatology; Hospices Civils de Lyon; Pierre-Bénite France

9. Department of Statistics unit; Hospices Civils de Lyon; Pierre-Bénite France

10. CNRS, UMR 5558 Biometry and Evolutionary Biology Laboratory; Université Lyon 1; Villeurbanne France

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ijc.32132/fullpdf

Reference31 articles.

1. US Food and Drug Administration 2012 http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm267829.htm

2. Committee for Medicinal Products for Human Use (CHMP) E http//www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/01/WC500069668.pdf

3. Regulatory T cells, tumour immunity and immunotherapy;Zou;Nat Rev Immunol,2006

4. Recombinant human Interleukin-2, recombinant human interferon Alfa-2a, or both in metastatic renal-cell carcinoma;Negrier;N Engl J Med,1998

5. Randomized study of high-dose and low-dose Interleukin-2 in patients with metastatic renal cancer;Yang;J Clin Oncol,2003

Cited by 152 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review;Frontiers in Immunology;2024-01-12

2. Severe Dysphagia With Eosinophilic Esophagitis Pattern of Injury Related to Pembrolizumab Therapy;ACG Case Reports Journal;2024-01

3. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes;The Lancet Neurology;2024-01

4. Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients – A case report and review of the literature;Heliyon;2024-01

5. A multicenter retrospective analysis: Factors influencing hepatic adverse events induced by immunotherapy in advanced liver cancer;Cancer Reports;2023-12-11